𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Specific and nonspecific macromolecule–drug conjugates for the improvement of cancer chemotherapy

✍ Scribed by Ester Hurwitz


Publisher
Wiley (John Wiley & Sons)
Year
1983
Tongue
English
Weight
566 KB
Volume
22
Category
Article
ISSN
0006-3525

No coin nor oath required. For personal study only.

✦ Synopsis


Antineoplastic drugs such as daunomycin, adriamycin, methotrexate, 5-fluorouridine, cytosine arabinoside, and platinate were bound to antibodies directly or via a polymeric bridge. The drug antibody conjugates retained most oftheir drug and antibody activities when tested in oitro. Daunomycin-antibody conjugates were shown to penetrate tumor cells in the conjugated form. In animals, daunomycin-antibody conjugates were a t least as effective chemotherapeutically as the corresponding free drugs and considerably less toxic. In some tumor systems, the daunomycin-antibody conjugates represented an improvement over the free drug. This improvement was restricted in some tumors to a particular injection route of'the tumor and the treatment.


📜 SIMILAR VOLUMES


Overlapping substrate specificities and
✍ Vincent J. Wacher; Chi-Yuan Wu; Leslie Z. Benet 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

A great challenge to the continuing search for more efficient and specific anticancer drugs is the unified response by tumor cells to rid themselves of these agents, a process loosely labeled multidrug resistance. While multidrug resistance has now become synonymous with the P-glycoprotein (P-gp) dr

Chemotherapy for advanced head and neck
✍ Edward T. Creagan; Thomas R. Fleming; John H. Edmonson; James N. Ingle; John E. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 294 KB 👁 3 views

Fourteen patients with advanced head and neck carcinomas received a monthly intravenous regimen of Adriamycin, 40 mg/m2, day 1; cyclophosphamide, 400 mg/m2, day 3; and cis-diamminedichloroplatinum, 20 mg/m2/1 hour, days 1-3 (CAP-3). A regression rate of only 7% (0112 squamous cell carcinomas; 112 ad